Literature DB >> 24234427

Ranibizumab in choroidal neovascularisation associated with ocular sarcoidosis.

Vasileios Efstathios Konidaris1, Theodoros Empeslidis.   

Abstract

An 81-year-old Caucasian man with a history of chronic bilateral panuveitis associated with sarcoidosis presented with visual acuity 1.0 LogMAR in the right and 0.5 LogMAR in the left eye. Following fluoroscein angiogram bilateral choroidal neovascular membrane was established. Treatment was initiated with a course of 3 monthly intravitreal injections of ranibizumab 0.5 mg in 0.05 mL bilaterally; oral prednisolone 30 mg/day on tapering doses controlled the ocular inflammation prior to the treatment with intravitreal injections. An additional two intravitreal ranibizumab injections were administered in the right eye. Fibrotic tissue in the posterior pole bilaterally was present on funduscopy following ranibizumab treatment. Visual acuity was LogMAR 1.6 in the right and 1.0 LogMAR in the left eye in 1 year follow-up. This case report summarises the issues of choroidal neovascularisation as a complication secondary to panuveitis associated with sarcoidosis and highlights the treatment of this complication with antivascular endothelial growth factor agents.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24234427      PMCID: PMC3830385          DOI: 10.1136/bcr-2013-010288

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  20 in total

1.  Neuro-ophthalmic manifestations of sarcoidosis: clinical spectrum, evaluation, and management.

Authors:  L P Frohman; R Grigorian; L Bielory
Journal:  J Neuroophthalmol       Date:  2001-06       Impact factor: 3.042

Review 2.  [Inflammatory choroidal neovascularisations].

Authors:  S Winterhalter; A M Joussen; U Pleyer; N Stübiger
Journal:  Klin Monbl Augenheilkd       Date:  2012-09-12       Impact factor: 0.700

Review 3.  Sarcoidosis.

Authors:  Robert P Baughman; Elyse E Lower; Roland M du Bois
Journal:  Lancet       Date:  2003-03-29       Impact factor: 79.321

4.  Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization.

Authors:  Subrata Mandal; Satpal Garg; Pradeep Venkatesh; Charu Mithal; Rajpal Vohra; Abhas Mehrotra
Journal:  Arch Ophthalmol       Date:  2007-11

5.  Intravitreal bevacizumab for treatment of uveitic macular edema.

Authors:  Miguel Cordero Coma; Lucia Sobrin; Sumru Onal; William Christen; C Stephen Foster
Journal:  Ophthalmology       Date:  2007-03-23       Impact factor: 12.079

6.  Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.

Authors:  Daniel Kook; Atmin Wolf; Thomas Kreutzer; Aljoscha Neubauer; Rupert Strauss; Michael Ulbig; Anslem Kampik; Christos Haritoglou
Journal:  Retina       Date:  2008-10       Impact factor: 4.256

7.  Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization.

Authors:  Alfredo Adán; Carlos Mateo; Rafael Navarro; Elena Bitrian; Ricardo P Casaroli-Marano
Journal:  Retina       Date:  2007 Nov-Dec       Impact factor: 4.256

8.  Sarcoidosis and its ophthalmic manifestations.

Authors:  C D Obenauf; H E Shaw; C F Sydnor; G K Klintworth
Journal:  Am J Ophthalmol       Date:  1978-11       Impact factor: 5.258

9.  Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis.

Authors:  Ramin Schadlu; Kevin J Blinder; Gaurav K Shah; Nancy M Holekamp; Matthew A Thomas; M Gilbert Grand; Nicholas E Engelbrecht; Rajendra S Apte; Daniel P Joseph; Anita G Prasad; Bradley T Smith; Arsham Sheybani
Journal:  Am J Ophthalmol       Date:  2008-03-05       Impact factor: 5.258

10.  Ocular sarcoidosis in a Korean population.

Authors:  Sun Young Lee; Hee Gyung Lee; Dong Soon Kim; June-Gone Kim; Hyewon Chung; Young Hee Yoon
Journal:  J Korean Med Sci       Date:  2009-06-12       Impact factor: 2.153

View more
  1 in total

1.  Peripapillary Choroidal Neovascular Membrane Secondary to Sarcoidosis-Related Panuveitis: Treatment with Aflibercept and Ranibizumab with a 50-month Follow-Up.

Authors:  Artemis Matsou; Maria Dermenoudi; Despina Tzetzi; Tryfon Rotsos; Olga Makri; Eleftherios Anastasopoulos; Chrysanthos Symeonidis
Journal:  Case Rep Ophthalmol       Date:  2021-04-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.